OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAetnaPolicy 0088

Antepartum Fetal Surveillance

Customize your policy alerts

Sign up for Aetna Policy 0088 alerts

Get alerted when Policy 0088 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity and coverage for antepartum fetal surveillance tests (NST, CST, BPP, modified BPP, umbilical artery and middle cerebral artery Doppler, and measurement of sFlt-1/PlGF ratio) for pregnant women with specified risk factors and clinical scenarios, per ACOG guidance. Applies to in-office and in-hospital testing reviewed by Aetna.

Policy Summary

PayerAetna

PolicyAntepartum Fetal Surveillance

Policy CodePolicy 0088

Change TypeNo material changes

Effective DateJan 12, 1996

Last ReviewAug 5, 2026

Next Review DateJan 8, 2026

Key ActionDocument clinical risk factors, gestational age, and test components when ordering or performing antepartum fetal surveillance.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

01/12/1996policy effective date

01/08/2026next scheduled review

32-34wusual GA to begin testing

26wGA for high-risk start

23+0–34+6wsFlt-1/PlGF window

76818,76819,59025example covered CPTs

Coverage Criteria for Antepartum Fetal Surveillance

inv-01: Antepartum fetal surveillance — timing and indications

Covered when ALL of the following are met

Antepartum fetal surveillance (NST, CST, BPP, modified BPP): Used for women with risk factors for stillbirth due to utero-placental insufficiency; testing should begin when interventions can be undertaken; for most increased-risk pregnancies begin at 32–34 weeks of gestation, or at 26 weeks for multiple or particularly worrisome high-risk conditions.gestational age criteria

Examples of high-risk conditions include bleeding, chronic or pregnancy-induced hypertension, collagen vascular disease (including antiphospholipid syndrome), fetal growth restriction, gestational diabetes, impaired renal function, maternal heart disease (NYHA Class III or IV), oligohydramnios, significant isoimmunization, steroid-dependent or poorly controlled asthma.

inv-02: Repeat testing

Covered when ANY of the following persistence conditions apply

Repeat testing:

Policy Summary

PayerAetna

PolicyAntepartum Fetal Surveillance

Policy CodePolicy 0088

Change TypeNo material changes

Effective DateJan 12, 1996

Last ReviewAug 5, 2026

Next Review DateJan 8, 2026

Key ActionDocument clinical risk factors, gestational age, and test components when ordering or performing antepartum fetal surveillance.

SourceLink

On This Page

inv-04: Doppler velocimetry indications (umbilical artery and MCA)

Covered when ALL of the following are met

Umbilical artery Doppler: Medically necessary in pregnancies with intrauterine growth restriction (fetus with estimated fetal weight or abdominal circumference <10th percentile) or oligohydramnios; in monochorionic twin pregnancies, used for screening to monitor for TTTS, TAPS, and discordant growth beginning at 16 weeks when criteria are met.IUGR defined as <10th percentile; start at 16 weeks for monochorionic twin screening

Decisions about timing of delivery should integrate Doppler results with other fetal well-being tests and maternal status.

Middle cerebral artery Doppler: Medically necessary for suspected fetal anemia (eg, isoimmunization, parvovirus B19) and for screening monochorionic twin pregnancies for TTTS and TAPS beginning at 16 weeks when criteria are met.start at 16 weeks for monochorionic twin screening

inv-06: Clinical evidence and implied coverage stance

Summary of clinical utility and evidence-based guidance from the document:

Fetal movement assessment: Maternal perception/counting of fetal movements (‘kick counts’) is supported and associated with improved perinatal outcomes, but no validated quantitative alarm limit exists; use as part of antepartum surveillance.

Non-stress test (NST) and remote NST: NST assesses fetal heart rate accelerations with movement or acoustic stimulation; remote/home NST and telemonitoring have emerging feasibility and safety data and may be appropriate in selected high-risk pregnancies per recent trials and pilot studies.

Biophysical profile (BPP) and modified BPP: BPP comprises five components (AFI, breathing, movement, tone, NST) scored 0–10; randomized trial evidence is insufficient to definitively support BPP as a test of fetal wellbeing in high-risk pregnancies per Cochrane review.

Document BPP components and resulting score when performed.

Contraction stress test (CST): CST evaluates fetal heart rate response to uterine contractions but is rarely used in current practice; consider less invasive tests first.

Uterine/umbilical artery Doppler: Umbilical artery Doppler is supported for surveillance when IUGR is suspected and should be started when fetus is viable; routine uterine artery Doppler screening in low-risk populations is not supported by evidence.

Doppler of vessels other than umbilical artery and MCA is considered investigational for routine surveillance.

inv-07: Use of umbilical artery Doppler

Covered/appropriate when used in the evaluation of suspected intrauterine growth restriction (IUGR) or other high-risk fetal conditions and integrated with other fetal testing:

Umbilical artery Doppler in IUGR: Use when IUGR is suspected or diagnosed; interpret results together with NST, BPP, amniotic fluid assessment, and maternal status to inform timing of delivery.

Not recommended as routine screening in low-risk pregnancies; evidence shows Doppler reduces interventions and may improve outcomes in IUGR.

inv-08: Use of MCA PSV

Appropriate for assessment of fetal anemia in red-cell alloimmunization:

MCA PSV for alloimmunization: Use serial MCA PSV measurements to screen for moderate-to-severe fetal anemia and reduce need for invasive procedures; elevated MCA PSV correlates with lower fetal hematocrit and has high sensitivity for severe anemia.MCA PSV thresholds (eg, >1.5 MoM for TAPS) and gestational age–adjusted values apply; false positives increase after 33 weeks.

High sensitivity (reported ~93%) supports clinical applicability to reduce cordocentesis.

inv-09: Third-trimester UAD in late SGA

Useful as part of multi-test assessment in suspected late SGA (>=32 weeks):

Third-trimester UAD: Abnormal third‑trimester uterine artery Doppler (eg, PI >95th percentile or ≥2 SD, bilateral notching) is associated with increased risk of perinatal mortality and adverse outcomes and should be combined with other tests to guide management in suspected late SGA (≥32 weeks).Uterine artery PI >95th percentile or ≥2 SD; gestational age ≥32 weeks

Predictive accuracy highest for perinatal mortality (AUC reported ~0.90); limited utility as a standalone test.

inv-10: Doppler in multiple gestations, TTTS, and TAPS

Doppler incorporated into surveillance for monochorionic twin complications per specialty guidance:

Twin surveillance (MCDA): Begin ultrasound surveillance for TTTS at 16 weeks and continue at least every 2 weeks for monochorionic‑diamniotic twins; include amniotic fluid assessment and ideally umbilical artery Doppler; consider MCA PSV for TAPS screening with thresholds (eg, MCA‑PSV >1.5 MoM in donor and <1.0 MoM in recipient or intertwin Δ >0.5 MoM).Start at 16 weeks; surveillance interval at least every 2 weeks

Refer patients meeting criteria for fetal intervention (eg, laser) to a specialized fetal intervention center.

inv-11: Evidence-supported clinical indications

Clinical scenarios and evidence where sFlt-1/PlGF measurement has demonstrated utility:

Short-term rule-out/prediction: sFlt-1/PlGF ratio can rule out development of preeclampsia within 1 week (PROGNOSIS: ratio ≤38, NPV 99.3%) and within 2 weeks in certain cohorts; adds predictive value to clinical models, particularly before 35 weeks.sFlt-1/PlGF ≤38

Utility diminishes after 35 weeks; use with clinical assessment.

Chronic hypertension with suspected superimposed PE: Addition of angiogenic markers improved detection of superimposed PE within 1 week (reported AUC ~0.91) and increased detection rates for maternal and perinatal adverse outcomes.

Investigators suggested consideration of implementation in this population.

Pregnancies with fetal growth restriction: sFlt-1/PlGF outperformed individual markers for predicting PE in pregnancies with FGR; established cut-off (<38) was effective for short-term rule-out in this cohort though performance declines after 2 weeks.sFlt-1/PlGF <38

Twin pregnancies: sFlt-1/PlGF ratio may predict selective fetal growth restriction and correlate with time‑to‑delivery in twin pregnancies, but different cut-offs may be required and performance for composite adverse perinatal outcome was limited in small cohorts.

Screening/diagnostic context: Combining angiogenic markers with clinical risk factors and ultrasound markers improves screening accuracy for early‑ and late‑onset PE; no single marker is sufficient alone and combined models lack extensive external validation.various

Prospective validation and standardized cut‑offs needed.

The policy lists specific tests and procedures considered experimental, investigational, or unproven because effectiveness has not been established. Examples include remote non‑stress testing (home, tele‑monitored, or virtual NST), Doppler studies of the ductus venosus and vessels other than the middle cerebral artery or umbilical artery for fetal growth surveillance, measurement of serum YKL‑40 for evaluation of pre‑eclampsia or SGA, and ophthalmic artery Doppler for prediction of pre‑eclampsia. The policy also identifies certain CPT codes (e.g., 83520, 93886, 93888) associated with these investigational indications and notes they are not covered for those purposes.

Coding and Clinical Measurements

Antepartum fetal surveillance CPT codes (covered if selection criteria are met)CPTCovered

59020	Fetal contraction stress test.
59025	Fetal non-stress test.
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> or = 14 weeks 0 days), transabdominal approach; single or first gestation.
76810	Each additional gestation (List separately in addition to code for primary procedure).
76818	Fetal biophysical profile; with non-stress testing.
76819	Fetal biophysical profile; without non-stress testing.

Umbilical artery DopplerCPTCovered

76820

Doppler velocimetry, fetal; umbilical artery.

Middle cerebral artery DopplerCPTCovered

76821

Doppler velocimetry, fetal; middle cerebral artery.

Preeclampsia sFlt-1/PlGF ratio (PERA) CPT codesHCPCSCovered

0482U	Obstetrics (preeclampsia), biochemical assay of soluble fmslike tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), serum, ratio reported for sFlt1/PlGF, with risk of progression for preeclampsia with severe features within 2 weeks.
0524U	Obstetrics (preeclampsia), sFlt-1/PlGF ratio, immunoassay, utilizing serum or plasma, reported as a value.

CPT codes not covered for certain investigational indicationsCPTNot Covered

83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified [not covered for serum YKL-40].
93886	Transcranial Doppler study of the intracranial arteries; complete study [not covered for prediction of pre-eclampsia].
93888	Transcranial Doppler study of the intracranial arteries; limited study [not covered for prediction of pre-eclampsia].

Example ICD-10 codes listed as covered when selection criteria are met (not all-inclusive)ICD-10Covered

D68.61	Antiphospholipid syndrome.
E10.10 - E10.A2	Type 1 diabetes mellitus.
E11.00 - E11.9	Type II diabetes mellitus.
I50.1 - I51.9	Heart failure.
J45.20 - J45.998	Asthma [steroid dependent or poorly controlled].

Regulatory / device approvals referencedmixed

FDA May 2023

Regulatory approval noted for sFlt-1:PlGF test in hospitalized singleton patients with hypertensive disorders

No explicit CPT/ICD/HCPCS codes in this segmentmixed

No codes listed

Gestational age threshold for antepartum testing

Usual gestational age to begin antepartum surveillance (most increased-risk pregnancies)Begin testing at 32–34 weeks gestation.

Earlier initiation for multiple or particularly worrisome high‑risk conditionsBegin testing at 26 weeks gestation.

RationaleStart when interventions can be undertaken and based on presence of maternal or pregnancy-related risk factors (e.g., bleeding, hypertensive disorders, antiphospholipid syndrome, fetal growth restriction, oligohydramnios).

sFlt-1/PlGF testing window

sFlt-1/PlGF testing window (hospitalized singleton pregnancies with hypertensive disorders)23+0 to 34+6 weeks gestation.

Use contextMeasurement considered medically necessary for pregnant women with singleton pregnancies hospitalized for hypertensive disorders of pregnancy within this window.

RecommendationShould be used in conjunction with other clinical assessments rather than as a standalone diagnostic test.

PMDV cut-off

Ophthalmic artery PMDV cut-off>22.11 cm/s (best cut-off reported for predicting pre-eclampsia in Matias et al, sensitivity 70%, specificity 75%).

Performance notePMDV contributed to improved AUC when added to clinical models; reported AUC 0.73 in the cohort study.

Clinical implicationDocument exact parameter measured and gestational age when reporting PMDV values for interpretation within models.

First diastolic peak velocity cut-off (ophthalmic artery)

First diastolic peak velocity (ophthalmic artery) cut-off23.3 cm/s (cut-off shown to predict early-onset PE; pooled sensitivity ~61% and specificity ~73%).

Performance caveatLower sensitivity for late-onset PE (about 39%); overall AUC 0.68 for early-onset PE in meta-analysis.

InterpretationUse along with other clinical and Doppler indices; not recommended as sole screening test.

IMA diagnostic accuracy summary

IMA diagnostic accuracy (pooled meta-analysis)AUC 0.860; sensitivity 0.80; specificity 0.76.

Study contextBased on a diagnostic test accuracy meta-analysis of IMA for detecting preeclampsia (6 included studies).

LimitationAuthors recommend further research and clinical validation despite promising pooled accuracy.

Fixed false-positive rate used in models

Reported AUC for IMA/IMA-related modelsAUC 0.860 reported for IMA in pooled analysis (see IMA diagnostic accuracy).

Model detection performance at fixed FPRsModels in reviewed studies reported detection rates at fixed false-positive rates of 5% and 10%.

Fixed false-positive rates used in modeling5%–10% (models reported DR at fixed FPRs of 5% and 10%).

sFlt-1/PlGF ratio cutoffs

PROGNOSIS study rule‑out cutoffsFlt-1/PlGF ≤38 rules out preeclampsia within 1 week (NPV 99.3%).

FGR cohort rule‑out cutoffsFlt-1/PlGF <38 ruled out PE within 2 weeks in a growth‑restricted cohort (NPV 93.3%).

Early‑onset PE cutoffssFlt-1/PlGF 33 ruled out early‑onset PE (high sensitivity/specificity); sFlt-1/PlGF 88 predicted early‑onset PE (high specificity).

Oligohydramnios definition

Oligohydramnios definition (deepest vertical pocket)Deepest vertical pocket ≤2 cm.

Oligohydramnios definition (AFI)Amniotic fluid index (AFI) ≤5 cm.

Measurement noteEvidence supports using the deepest vertical pocket method (fewer interventions) and it should be used in multiple pregnancies; document method used.

Polyhydramnios (moderate/severe)

Polyhydramnios (moderate/severe) definition — deepest vertical pocketDeepest vertical pocket ≥12 cm.

Polyhydramnios (moderate/severe) definition — AFIAmniotic fluid index (AFI) ≥30 cm.

Severity categoriesPolyhydramnios frequently categorized as mild/moderate/severe using deepest pocket ranges (8–11 cm, 12–15 cm, ≥16 cm) or AFI ranges (24–29.9, 30–34.9, ≥35 cm).

Provider Actions, Prior Authorization, and Documentation

Prior Authorization
Prior authorization — covered CPT/HCPCS codes require criteria to be met
CPT/HCPCS codes for antepartum fetal surveillance (e.g., 59020, 59025, 76805, 76810, 76818, 76819, 76820, 76821, 0482U, 0524U) are listed in the policy as covered when the policy's selection criteria are met; ensure the clinical indications and gestational-age thresholds in the policy are documented when billing these codes and follow any payer prior-authorization rules that apply.
Examples of covered procedure codes: 59020, 59025, 76805, 76810, 76818, 76819.
Doppler and biomarker codes listed as covered when criteria met: 76820 (umbilical artery Doppler), 76821 (MCA Doppler), 0482U and 0524U (sFlt‑1/PlGF assays).

Prior Authorization
Prior authorization may be required for remote monitoring
Remote/home non‑stress testing and telemonitoring are described as emerging and feasible alternatives with evidence of non‑inferiority in selected high‑risk pregnancies; confirm plan requirements and prior‑authorization rules for home fetal monitoring devices and telemonitoring programs before ordering or billing.
Studies cited show feasibility and non‑inferiority (e.g., INVU study: >90% acceptable NSTs remotely).
Policy explicitly advises to confirm payer policy for prior authorization for home fetal monitoring and telemonitoring.

Prior Authorization
Prior authorization expectation for Doppler in suspected IUGR
Umbilical artery Doppler velocimetry is supported when intrauterine growth restriction (IUGR) is suspected or diagnosed and should be interpreted with other fetal assessments; routine Doppler screening in low‑risk pregnancies is not supported by evidence.
Use Doppler to inform timing of delivery in suspected IUGR and integrate results with NST, BPP, amniotic fluid assessment, and maternal status.
Policy notes Doppler reduces some interventions in IUGR but is not recommended as routine screening in low‑risk populations.

Note
No specific prior authorization stated in background text
The background and policy text do not specify any standalone prior‑authorization requirements for the described antepartum fetal surveillance tests in this segment; practitioners should still verify plan‑specific preauthorization rules separately.
Background sections summarize clinical evidence but do not list explicit prior‑authorization procedures or rules.
Policy history and administrative notes further indicate plan provisions govern coverage determinations.

Note
Prior authorization / regulatory context for sFlt‑1/PlGF assays
The document references FDA approval (May 2023) of the sFlt‑1/PlGF test for hospitalized singleton patients with hypertensive disorders and recommends using the test with other clinical assessments; it does not define payer prior‑authorization procedures for this assay.
FDA approval noted May 2023 for sFlt‑1:PlGF in hospitalized singleton pregnancies with hypertensive disorders.
Policy advises the test should be used in conjunction with other laboratory tests and clinical assessments.

Note
No explicit prior authorization requirements for antepartum surveillance in this excerpt
This excerpt does not list specific prior‑authorization requirements for routine antepartum fetal surveillance services (NST, CST, BPP, modified BPP, Doppler); providers should follow plan rules and document clinical indications per the policy when requesting coverage.
Policy outlines medical‑necessity criteria but the excerpt contains no explicit preauthorization triggers.
Providers remain responsible for verifying plan‑specific authorization requirements.

Note
Prior authorization not specified in policy history section
Policy history and review dates are provided, but this section does not list procedure codes requiring prior authorization; confirm authorization requirements with the payer for the specific patient and service.
Last review date and effective/next review dates are shown; policy content does not substitute for plan authorization rules.
Clinical Policy Bulletins are descriptive and not a guarantee of coverage.

Step Therapy
Order CST or full BPP after abnormal NST as indicated
Following an abnormal NST or modified BPP, a contraction stress test (CST) or a full biophysical profile (BPP) is considered medically necessary; subsequent management should be based on CST/BPP results, gestational age, oligohydramnios severity, and maternal condition.
Policy statement: 'A CST or full BPP is considered medically necessary following an abnormal NST or modified BPP.'
Management decisions should incorporate CST/BPP findings and clinical context.

Step Therapy
CST is uncommon — consider NST/BPP first
The CST is described as rarely used in current clinical practice; consider less invasive options (NST, BPP) before performing a CST when clinically appropriate.
CST overview: test lasts until 3 moderate contractions in 10 minutes; often not used clinically.
Policy emphasizes CST's uncommon role and suggests alternatives be considered first.

Step Therapy
Use UAD as part of a sequential, multi‑test approach in late SGA
For suspected late small‑for‑gestational‑age (SGA) fetuses (≥32 weeks), uterine artery Doppler (UAD) or other third‑trimester UAD assessments should be used as part of a multi‑test strategy rather than relied on as a standalone test to guide management.
Policy notes limited predictive ability of UAD as a stand‑alone test and recommends combining Doppler with other fetal assessments.
Third‑trimester abnormal UAD is moderately useful for predicting perinatal death in late SGA but should inform, not dictate, decisions.

Note
No mandated testing order or step therapy sequencing specified
The policy does not mandate a specific testing sequence or step‑therapy algorithm beyond the recommended pathway after abnormal NST; studies evaluating combinations of markers and Doppler are summarized but no required stepwise ordering is specified.
Document summarizes combination models and detection rates but explicitly states no mandated testing order is described.
Providers should apply clinical judgment and follow policy criteria when selecting tests.

Documentation Required
Document clinical indications, risk factors, and gestational age for testing
Document clinical indications and gestational age when ordering antepartum fetal surveillance tests; if repeat testing is performed, document persistence of the condition or acute changes (e.g., decreased fetal movement) that justify repeat testing.
Policy requires tests be ordered for specified maternal, pregnancy‑related, or fetal risk factors and notes gestational‑age thresholds for initiation (e.g., 32–34 weeks or 26 weeks for high‑risk conditions).
Repeat testing is medically necessary if the provoking condition persists or with clinical deterioration.

Documentation Required
Document BPP components and scores
When performing a Biophysical Profile (BPP) or modified BPP, document each component and the resulting score; for modified BPP, document NST findings and the amniotic fluid assessment used.
BPP components to document: amniotic fluid index, fetal breathing, fetal movement, fetal tone, and NST, with score 0–10.
Modified BPP: document NST findings and amniotic fluid index.

Documentation Required
Document integration of Doppler results with other assessments to support management
When umbilical artery Doppler is used for surveillance of suspected IUGR, document how Doppler results were integrated with other fetal assessments (amniotic fluid, NST, CST, BPP) and maternal status to support timing‑of‑delivery decisions.
ACOG guidance cited: decisions regarding timing of delivery should combine Doppler findings with other tests of fetal well‑being and maternal monitoring.
Policy emphasizes interpreting Doppler in the broader clinical context rather than as a standalone determinant.

Documentation Required
Document exact Doppler/biomarker parameters and cutoffs used
Studies report specific measured Doppler and biomarker parameters and cutoffs (for example, ophthalmic artery PMDV >22.11 cm/s); document the exact parameter measured, gestational age, and any combined model components used when reporting these results.
Example cutoff: ophthalmic artery PMDV >22.11 cm/s associated with PE prediction (sensitivity 70%, specificity 75%).
Policy notes that combined models incorporate clinical variables and biomarkers; document components for clinical interpretation.

Documentation Required
Documentation note — sFlt‑1/PlGF approval noted; verify authorization process
The policy notes no explicit documentation or prior‑authorization procedural requirements in these sections but highlights the FDA approval (May 2023) for the sFlt‑1/PlGF assay in hospitalized singleton patients; providers should follow plan rules for authorization and document clinical context when ordering this test.
FDA approval for sFlt‑1:PlGF in May 2023 is noted; the test should be used with other clinical assessments.
No procedural prior‑authorization process for the assay is defined in the excerpt—verify with payer.

Documentation Required
Use policy glossary terms in clinical documentation
Use the policy's glossary terms (e.g., fetal growth restriction, oligohydramnios, polyhydramnios) in clinical documentation to clearly support the indication for surveillance testing.
Examples: Fetal growth restriction defined as estimated fetal weight or abdominal circumference <10th percentile; oligohydramnios defined by deepest vertical pocket ≤2 cm or AFI ≤5 cm.
Using standard terminology from the policy helps substantiate medical necessity.

Denial Risk
Denial risk — experimental, investigational, or unproven tests
Tests identified in the policy as experimental, investigational, or unproven (including remote non‑stress testing, Doppler of ductus venosus or vessels other than umbilical/MCA, uterine artery Doppler for routine screening, serum YKL‑40, ophthalmic artery Doppler, and Preeclampsia Screen|T1) may not be established and could trigger coverage denial if billed for the excluded indications.
Policy lists remote NST (home/tele‑monitored) and several Doppler/biomarker tests as experimental or unproven for the indications noted.
Billing these procedures for indications not listed as medically necessary risks denial.

Denial Risk
Denial risk — routine Doppler in low‑risk populations not supported
Routine use of uterine artery Doppler or routine Doppler screening in low‑risk or unselected populations is not supported by the evidence; ordering such routine Doppler surveillance without clinical indication could risk denial.
Cochrane review cited: routine fetal and umbilical Doppler in low‑risk populations did not improve primary outcomes and is not supported for routine screening.
Policy states Doppler is most applicable in already defined high‑risk populations.

Denial Risk
Denial risk — order Doppler only with documented clinical indication
The policy emphasizes that umbilical or uterine artery Doppler should not be used as routine screening in low‑risk or unselected pregnancies; order Doppler testing only when clinical suspicion (e.g., suspected IUGR, oligohydramnios, multiple gestation complications) is documented to support coverage.
ACOG guidance quoted: Doppler not shown to be of value as a screening test in the general obstetric population.
Policy recommends Doppler primarily when IUGR is suspected and to integrate findings with other assessments.

Billing Rule
No explicit coverage/billing rules in background — verify payer requirements
The policy's background sections do not state explicit authorization, coverage, or billing requirements; providers should rely on the documented medical‑necessity criteria in the policy and confirm any payer authorization or billing rules separately.
Background and evidence summaries are descriptive and do not replace plan authorization rules.
Confirm coverage and preauthorization processes with the payer before billing.

Prior Authorization
No explicit preauthorization triggers stated — confirm with payer
The document segment does not state explicit preauthorization triggers; nevertheless, providers remain responsible for verifying plan‑specific prior‑authorization requirements before ordering and billing services.
Policy describes clinical indications and FDA approval context but does not list automatic preauthorization triggers.
Verify member's plan provisions for prior authorization.

Background and Evidence Summary

Antepartum fetal surveillance is intended to assess risk of adverse perinatal outcomes related to utero‑placental insufficiency and fetal hypoxia. Common surveillance methods include maternal fetal movement assessment, NST, BPP (five components scored 0–10), modified BPP, and Doppler velocimetry of the umbilical and middle cerebral arteries. Testing is targeted to pregnancies with maternal or pregnancy‑related risk factors (for example, decreased fetal movement, IUGR, oligohydramnios, isoimmunization, multiple gestation with growth discrepancy, hypertensive disorders, or prior fetal demise) and should be timed so that interventions are possible based on gestational age.

inv-21: Evidence point — Routine fetal and uterine artery Doppler in low-risk populations not shown to benefit mother or baby

Summary evidence point

Routine Doppler in low-risk populations: Routine fetal and uterine artery Doppler ultrasound in low‑risk or unselected populations has not been shown to benefit mother or baby and is therefore not supported as routine screening.

Cochrane reviews and guideline assessments found no improvement in perinatal mortality or neonatal morbidity with routine Doppler in low‑risk groups.

Recommendations and coverage considerations in the policy are informed by major guideline sources including ACOG practice bulletins and committee opinions (for example, guidance on umbilical artery Doppler and management of preeclampsia) and systematic evidence reviews. These guidelines support targeted use of Doppler in suspected IUGR and caution against routine Doppler screening in low‑risk populations.

Clinical evidence summarized in the policy includes randomized trials, cohort studies, and systematic reviews. Cochrane reviews found no benefit from routine fetal/umbilical Doppler screening in unselected populations, while trials in high‑risk pregnancies showed that umbilical artery Doppler can reduce interventions and perinatal death. Evidence for biomarkers such as sFlt‑1/PlGF demonstrates utility for short‑term rule‑out of preeclampsia (for example, ratio ≤38 in PROGNOSIS) and improved predictive accuracy when combined with clinical or ultrasound markers, but broader validation and implementation considerations remain.

Definitions and Test Descriptions

Oligohydramnios — definition variants and policy note

Oligohydramnios definition variantsDescribed variably (absence of a vertical pocket ≥2 cm or AFI <5 cm); deepest vertical pocket method preferred due to fewer interventions.

Evidence notePolicy notes best available evidence supports deepest vertical pocket method over AFI for singleton pregnancies; use deepest pocket in multiples.

Policy statusOligohydramnios definitions included in glossary and used to inform testing and management thresholds.

Intrauterine growth restriction (IUGR)

Intrauterine growth restriction (IUGR) definitionFetus with estimated fetal weight or abdominal circumference <10th percentile for gestational age.

Clinical useUmbilical artery Doppler is considered medically necessary when IUGR is suspected; Doppler should begin when fetus is viable.

SynonymFetal growth restriction (FGR) is used interchangeably in the policy glossary.

Discordant fetal growth (twins)

Discordant fetal growth (twins) definitionDefined as a 15–25% reduction in estimated fetal weight of the smaller fetus compared with the larger fetus.

Twin surveillanceScreening in monochorionic twins begins at 16 weeks and includes Doppler for TTTS/TAPS and discordant growth when criteria met.

DocumentationUse standardized terminology for discordance in clinical records to support surveillance decisions.

Fetal movement assessment

Fetal movement assessmentMaternal perception/counting of fetal movements ('kick counts') used as an antepartum surveillance tool associated with improved perinatal outcomes.

LimitationNo validated quantitative alarm limit; organized screening has variable uptake among clinicians.

Clinical recommendationUse maternal fetal‐movement assessment as part of antepartum surveillance, document concerns prompting further testing.

Non-Stress Test (NST)

Non‑Stress Test (NST) descriptionExternal fetal heart rate monitoring assessing accelerations associated with fetal movement or after acoustic stimulation to evaluate fetal autonomic function.

Procedure noteMother denotes fetal movement; fetal heart rate tracing evaluated for accelerations; acoustic stimulation may be applied up to 3 times if needed.

Clinical roleUsed as a component of BPP or modified BPP and as an initial surveillance test prompting further testing if abnormal.

Biophysical Profile (BPP)

Biophysical Profile (BPP) componentsFive components: amniotic fluid index, fetal breathing movements, fetal movement, fetal tone, and NST; each scored 0–2 for total 0–10.

Scoring interpretationScores 8–10 normal, 6 borderline, <6 concerning/problematic.

DocumentationWhen performing BPP, document each component and resulting score to support management decisions.

Modified BPP

Modified BPP descriptionCombines an NST (short‑term indicator) with the amniotic fluid index (long‑term placental function indicator).

Clinical roleProvides a quicker assessment than full BPP while incorporating both short‑ and long‑term indicators of fetal well‑being.

Follow‑upAbnormal modified BPP typically prompts full BPP or CST as next‑step testing per policy guidance.

Contraction Stress Test (CST)

Contraction Stress Test (CST) descriptionAssesses fetal heart rate response to uterine contractions; test lasts until mother has 3 moderate contractions within 10 minutes.

UsageRarely used in current clinical practice; considered medically necessary following an abnormal NST or modified BPP when indicated.

Administration noteIf contractions are not spontaneous, they may be induced with IV oxytocin to achieve required contractions.

Uterine artery Doppler

Uterine artery Doppler definitionUltrasound Doppler assessment of uterine artery blood flow (e.g., PI, RI, notching) used to assess risk of preeclampsia and IUGR.

Predictive value caveatPredictive value for PE and IUGR is variable; routine uterine artery screening in low‑risk populations is not supported by evidence.

Clinical recommendationReserve uterine artery Doppler for selected high‑risk assessments and research protocols; interpret with other clinical data.

Umbilical artery Doppler velocimetry

Umbilical artery Doppler velocimetry definitionSonographic assessment of umbilical artery flow velocity waveforms to detect high‑resistance patterns (e.g., low, absent, or reversed end‑diastolic flow) associated with IUGR and fetal hypoxia.

Clinical impactRCTs showed reduced antenatal monitoring and some reductions in interventions; use when IUGR suspected and interpret with other fetal tests.

TimingStart when the fetus is viable and IUGR is suspected.

Middle Cerebral Artery Peak Systolic Velocity (MCA PSV)

MCA PSV useDoppler measurement of peak systolic flow in the fetal middle cerebral artery used to screen for fetal anemia; elevated MCA PSV correlates with lower fetal hematocrit.

AccuracyOverall sensitivity ~93% for severe anemia and ~88% for moderate anemia; specificity ~75%; false positives increase after 33 weeks.

Clinical roleCan reduce need for invasive cordocentesis in alloimmunized pregnancies when used serially.

YKL-40

YKL-40 descriptionA 38‑kDa macrophage‑derived glycoprotein (Chitinase‑3‑Like Protein 1) explored as a potential biomarker for pre‑eclampsia and small‑for‑gestational‑age.

Study findingsLarge cohort studies showed associations with maternal age, BMI, and SGA but not consistently with pre‑eclampsia; evidence remains inconclusive.

Policy stanceMeasurement of serum YKL‑40 is considered experimental/investigational for evaluation of pre‑eclampsia or SGA in this policy.

YKL-40 — alternate identifier

Alternate identifier for YKL‑40Chitinase 3‑Like Protein 1 (Chondrex).

Biological notesExpressed by several tissues, implicated in inflammation and tissue remodeling; not organ‑specific.

Research noteNot validated for routine clinical use in preeclampsia prediction; considered investigational in policy.

Ophthalmic artery PMDV / PSV ratio

Ophthalmic artery PMDV / PSV ratioDoppler‑derived velocities from the maternal ophthalmic artery (e.g., PMDV and PSV ratios) evaluated as predictors of preeclampsia; PMDV >22.11 cm/s reported as a useful cut‑point.

Performance summaryIndividual studies reported AUCs in the 0.68–0.78 range; incorporation into multivariable models increased discriminatory ability.

Policy noteOphthalmic artery Doppler is listed among investigational tests for prediction of preeclampsia in this policy.

Ischemia-modified albumin (IMA)

Ischemia‑modified albumin (IMA) definitionA serological marker of oxidative stress proposed as a biomarker for preeclampsia.

Pooled accuracyMeta‑analysis reported pooled sensitivity 0.80, specificity 0.76, and AUC 0.860 for detecting PE.

Evidence gapFurther research and clinical validation recommended despite promising pooled accuracy.

sFlt-1/PlGF ratio

sFlt‑1/PlGF ratio definitionSerum ratio of soluble fms‑like tyrosine kinase‑1 (sFlt‑1) to placental growth factor (PlGF); an angiogenic imbalance marker used for PE prediction/monitoring.

Clinical usesUsed to rule out PE within short timeframes, predict PE in combination models, and aid monitoring of established PE; different cut‑offs reported for early vs late‑onset PE.

GuidancePROGNOSIS established a ≤38 cut‑off to rule out PE within 1 week (NPV 99.3%); other cut‑offs (33, 88, 110) reported for specific predictions.

sFlt-1/PlGF ratio — mechanism

Mechanism and descriptorThe sFlt‑1/PlGF ratio reflects anti‑angiogenic (sFlt‑1) versus pro‑angiogenic (PlGF) factors; elevated ratios indicate angiogenic imbalance associated with preeclampsia and placenta‑related disorders.

InterpretationPerformance is best for short‑term prediction and in combination with clinical and ultrasound markers; utility decreases after ~35 weeks.

Twin pregnancy noteDifferent cut‑offs may be required for twin pregnancies; interpret in context of chorionicity and other findings.

Fetal growth restriction (FGR)

Fetal growth restriction (FGR) definitionA fetus whose estimated fetal weight or abdominal circumference is less than the 10th percentile for its gestational age.

Clinical implicationFGR is an indication for umbilical artery Doppler surveillance per policy when criteria are met.

Synonym notePolicy uses both 'IUGR' and 'FGR' terminology interchangeably; documentation should reference the glossary definition.

Fetal growth restriction (FGR) — duplicate

Fetal growth restriction (duplicate entry)A fetus with estimated fetal weight or abdominal circumference <10th percentile for gestational age (policy glossary).

Use in criteriaUsed to trigger Doppler and intensified antepartum surveillance when present.

DocumentationRecord biometric percentiles and method used to support IUGR/FGR diagnosis.

Oligohydramnios — ultrasonographic definition

Oligohydramnios (ultrasound measurable vertical pocket) definitionNo ultrasonographically measurable vertical pocket >2 cm or AFI ≤5 cm; isolated oligohydramnios = single deepest pocket <2 cm.

Measurement preferenceDeepest vertical pocket method preferred; use this method in multiple pregnancies.

Clinical relevanceDegree of oligohydramnios influences management and further testing (e.g., need for CST/BPP).

Polyhydramnios (moderate or severe)

Polyhydramnios categories (deepest pocket/AFI ranges)Deepest pocket: mild 8–11 cm, moderate 12–15 cm, severe ≥16 cm; AFI: mild 24–29.9, moderate 30–34.9, severe ≥35 cm.

Policy cutoff for moderate/severeDeepest vertical pocket ≥12 cm or AFI ≥30 cm defines moderate or severe polyhydramnios.

Clinical noteSeverity classification guides monitoring and potential interventions.

Twin growth discordance

Twin growth discordance definitionSignificant size or weight difference between the two fetuses of a twin pregnancy.

Quantitative definition (policy body)Discordant fetal growth defined as a 15–25% reduction in estimated fetal weight of the smaller fetus compared with the larger fetus (policy footnotes).

Surveillance implicationDiscordance in monochorionic twins prompts screening from 16 weeks with Doppler for TTTS/TAPS and consideration of referral for fetal therapy when indicated.